Please visit answersincme.com/860/MED-ONC-03349-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts discuss how the latest data for first-line immunotherapy-based regimens informs personalized approaches for advanced NSCLC and how to elevate care through patient advocate–centered approaches. Upon completion of this activity, participants should be better able to: Differentiate the clinical profiles of NCCN-preferred first-line immunotherapy-based regimens for advanced NSCLC based on the latest data for disease with no actionable mutations and PD-L1 expression 50% or greater; Identify how first-line treatment selection varies for different patient subpopulations with advanced NSCLC with no actionable mutations and PD-L1 expression 50% or greater; and Apply patient-centered strategies to optimize the integration of immunotherapy-based regimens into first-line treatment plans of patients with advanced NSCLC with no actionable mutations and PD-L1 expression 50% or greater.

Please visit answersincme.com/860/TSG to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses evidence-based insights that inform the practical integration of adjuvant immunotherapy regimens into cutaneous squamous cell carcinoma (CSCC) care, based on available clinical data. Upon completion of this activity, participants should be better able to: Review the rationale for immunotherapy in the adjuvant treatment of patients with high-risk resected cutaneous squamous cell carcinoma (CSCC); Summarize the latest clinical trial data evaluating adjuvant immunotherapy in high-risk CSCC; and Outline evidence-based, multidisciplinary strategies to optimize the care of patients with high-risk CSCC in the adjuvant setting.

Please visit answersincme.com/GTM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in sickle cell disease discusses comprehensive therapeutic selection strategies, from disease-modifying therapies to gene therapy options, and evidence-based approaches for optimizing patient outcomes across the disease spectrum. Upon completion of this activity, participants should be better able to: Review the impact that disease manifestations such as vaso-occlusive crises have on patients with sickle cell disease; Assess the efficacy and safety of available therapies for sickle cell disease and their implications for clinical practice; and Apply evidence-based strategies to optimize treatment outcomes in patients with severe sickle cell disease.

Please visit answersincme.com/860/240201294-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in chronic lymphocytic leukemia (CLL) use case examples to discuss how to select and sequence treatments for patients with CLL. Upon completion of this activity, participants should be better able to: Review guideline recommendations for preferred treatments in patients with CLL; Identify the clinical implications of the latest evidence informing the use of second-generation BTK inhibitors in patients with CLL; Outline practical strategies to optimize outcomes with second-generation BTK inhibitors in patients with CLL; and Describe emerging therapeutic agents currently under investigation for the treatment of CLL.

Please visit answersincme.com/860/98320325-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the evolving role of HER2-targeted antibody–drug conjugates (ADCs) and how to integrate them into clinical practice. Upon completion of this activity, participants should be better able to: Recognize the role of biomarker testing for the management of HER2-overexpressing NSCLC; Evaluate the clinical significance of new and emerging HER2-targeting ADCs for HER2-overexpressing NSCLC; and Apply strategies to optimize the use of HER2 targeting ADCs in patients with NSCLC.

Please visit answersincme.com/NPK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in multiple myeloma (MM) answers common questions about incorporating novel cereblon E3 ligase modulators (CELMoDs) in early-relapse therapy for patients with MM. Upon completion of this activity, participants should be better able to: Identify the rationale for incorporating novel CELMoDs in early-relapse therapy in patients with MM; Discuss the clinical impact of the latest data for emerging novel CELMoDs in the early-relapse setting for patients with MM; and Describe potential considerations for integrating novel CELMoDs in the treatment landscape of MM as they become available.

Please visit answersincme.com/FAH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastrointestinal cancer discusses strategies to integrate anti-EGFR therapies into the treatment of metastatic colorectal cancer. Upon completion of this activity, participants should be better able to: Describe the clinical significance of the latest evidence for anti-EGFR-based regimens for patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC); Outline strategies to optimize the integration of anti-EGFR-based regimens into management plans for patients with RAS/BRAF wild-type mCRC; and Review guideline recommendations for the management of RAS/BRAF wild-type mCRC.

Please visit answersincme.com/HSJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in urothelial cancer discusses biomarker testing for patients with locally advanced/metastatic urothelial cancer. Upon completion of this activity, participants should be better able to: Recognize the impact of biomarker testing on patient outcomes with novel approved therapies in locally advanced/metastatic UC (LA/mUC); Identify optimal strategies for implementing biomarker testing in clinical practice; and Outline patient-centered strategies to optimize outcomes following the identification of actionable biomarkers.

Please visit answersincme.com/PYP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in non–small-cell lung cancer (NSCLC) discusses TROP2-directed antibody-drug conjugates (ADCs) for the treatment of patients with advanced, pretreated EGFR-mutated NSCLC. Upon completion of this activity, participants should be better able to: Identify the rationale for using TROP2-directed ADCs in the treatment of patients with advanced, pretreated EGFR-mutated NSCLC; Review clinical evidence on emerging TROP2-directed ADCs in patients with advanced, pretreated EGFR-mutated NSCLC; and Outline evidence-based strategies to incorporate TROP2-directed ADCs for patients with advanced, pretreated EGFR-mutated NSCLC.

Please visit answersincme.com/860/97851223-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in lung cancer discuss the practical application of immunotherapy-based regimens for the treatment of extensive-stage small-cell lung cancer (ES-SCLC). Upon completion of this activity, participants should be better able to: Review the clinical impact of immunotherapy-based regimens for the management of small-cell lung cancer (SCLC); and Outline personalized treatment strategies to address key complexities affecting the optimal, real-world management of patients with SCLC.